$414 Million is the total value of GREAT POINT PARTNERS LLC's 30 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 61.1% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
EXEL | Sell | EXELIXIS INC | $29,471,000 | -7.9% | 1,300,000 | -25.7% | 7.12% | +0.2% |
XENE | Sell | XENON PHARMACEUTICALS INC | $28,124,000 | -5.2% | 920,000 | -3.2% | 6.80% | +3.1% |
RIGL | Sell | RIGEL PHARMACEUTICALS INC | $11,960,000 | -9.7% | 4,000,000 | -20.0% | 2.89% | -1.8% |
TCDA | Sell | TRICIDA INC | $10,275,000 | -23.2% | 1,250,000 | -10.7% | 2.48% | -16.5% |
NKTR | Sell | NEKTAR THERAPEUTICScall | $539,000 | -80.4% | 100,000 | -51.0% | 0.13% | -78.8% |
PASG | Sell | PASSAGE BIO INC | $353,000 | -96.3% | 113,900 | -92.5% | 0.08% | -96.0% |
RFL | Sell | RAFAEL HLDGS INC | $304,000 | -79.1% | 121,000 | -57.6% | 0.07% | -77.5% |
CABA | Exit | CABALETTA BIO INC | $0 | – | -472,433 | -100.0% | -0.40% | – |
ABUS | Exit | ARBUTUS BIOPHARMA CORP | $0 | – | -668,907 | -100.0% | -0.58% | – |
AGLE | Exit | AEGLEA BIOTHERAPEUTICS INC | $0 | – | -910,251 | -100.0% | -0.96% | – |
Exit | PYXIS ONCOLOGY INC | $0 | – | -400,000 | -100.0% | -0.98% | – | |
PRQR | Exit | PROQR THRAPEUTICS N V | $0 | – | -1,121,122 | -100.0% | -2.00% | – |
DYN | Exit | DYNE THERAPEUTICS INC | $0 | – | -845,000 | -100.0% | -2.23% | – |
RCKT | Exit | ROCKET PHARMACEUTICALS INC | $0 | – | -500,526 | -100.0% | -2.43% | – |
SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -145,405 | -100.0% | -2.91% | – |
MGNX | Exit | MACROGENICS INC | $0 | – | -1,000,000 | -100.0% | -3.57% | – |
BCAB | Exit | BIOATLA INC | $0 | – | -864,300 | -100.0% | -3.77% | – |
ARNA | Exit | ARENA PHARMACEUTICALS INC | $0 | – | -530,670 | -100.0% | -10.96% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
CYTOKINETICS INC | 18 | Q2 2024 | 7.1% |
IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Context Therapeutics Inc. | June 05, 2024 | 7,419,355 | 9.9% |
Outlook Therapeutics, Inc. | April 08, 2024 | 2,231,324 | 10.0% |
ALPINE IMMUNE SCIENCES, INC. | February 14, 2024 | 3,703,433 | 6.4% |
Avalo Therapeutics, Inc. | February 14, 2024 | 2,085 | 0.3% |
HERON THERAPEUTICS, INC. /DE/Sold out | February 14, 2024 | 0 | 0.0% |
Neurogene Inc. | February 14, 2024 | 994,229 | 7.8% |
OptiNose, Inc. | February 14, 2024 | 11,484,120 | 10.0% |
PRECISION BIOSCIENCES INCSold out | February 14, 2024 | 0 | 0.0% |
UroGen Pharma Ltd. | February 14, 2024 | 2,620,545 | 8.5% |
Vistagen Therapeutics, Inc. | February 14, 2024 | 2,792,927 | 10.0% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
N-PX | 2024-08-30 |
SC 13G | 2024-08-15 |
13F-HR | 2024-08-14 |
SC 13G | 2024-08-05 |
SC 13G | 2024-07-18 |
SC 13G | 2024-06-05 |
13F-HR | 2024-05-15 |
SC 13G | 2024-04-08 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.